Surgical Mesh Instruments Classification Will Be One Focus Of February Panel
This article was originally published in The Gray Sheet
FDA will hold an advisory panel meeting on urogynecological surgical mesh instrumentation on Feb. 26. The focus of the meeting will be whether to up-classify the devices from class I to class II with special controls, including a new 510(k) requirement.
You may also be interested in...
FDA issued final orders up-classifying surgical mesh for transvaginal repair of pelvic organ prolapse from class II to class III and calling for PMA standards, including clinical trial, animal studies, and materials testing data from new and existing manufacturers.
Oncology Center of Excellence is reviewing a research report on fluorouracil, and will next look to update cisplatin's label, but eventually must convince the reference product sponsor to submit the changes.
US FDA’s ‘Project Renewal’ requires lots of work and flexibility, Oncology Center of Excellence acknowledges. Side-benefit may be getting outside physicians to appreciate the value of drug labeling.